Spots Global Cancer Trial Database for advanced refractory solid tumors
Every month we try and update this database with for advanced refractory solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors | NCT03195764 | Advanced Refrac... | T-1101 (Tosylat... | 20 Years - | Taivex Therapeutics Corporation | |
| Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors | NCT01779336 | Advanced Refrac... | PL225B | 18 Years - 90 Years | Piramal Enterprises Limited | |
| A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors | NCT04200404 | Advanced Refrac... | CS1001 Regorafenib | 18 Years - | CStone Pharmaceuticals | |
| Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) | NCT04892498 | Advanced Refrac... | Hypofractionate... PD-1 inhibitor GM-CSF IL-2 | 18 Years - | Second Affiliated Hospital of Soochow University | |
| NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors | NCT02300467 | Advanced Refrac... | NOV120401 | 19 Years - | National OncoVenture | |
| Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors | NCT04685473 | Advanced Refrac... | T-1101 (Tosylat... | 20 Years - | Taivex Therapeutics Corporation | |
| Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors | NCT04324372 | Advanced Refrac... | HEC68498 | 18 Years - 70 Years | Sunshine Lake Pharma Co., Ltd. | |
| A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors | NCT04200404 | Advanced Refrac... | CS1001 Regorafenib | 18 Years - | CStone Pharmaceuticals | |
| An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors | NCT03349073 | Advanced Refrac... | T-1101 (Tosylat... | 20 Years - | Taivex Therapeutics Corporation | |
| Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors | NCT01779336 | Advanced Refrac... | PL225B | 18 Years - 90 Years | Piramal Enterprises Limited | |
| Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors | NCT03863145 | Advanced Refrac... Subjects Consid... | CB-03-10 | 18 Years - | Cosmo Pharmaceuticals NV | |
| Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | NCT05035745 | Advanced Refrac... Advanced Triple... Metastatic Trip... | Talazoparib Selinexor | 18 Years - 99 Years | National University Hospital, Singapore | |
| A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors | NCT04200404 | Advanced Refrac... | CS1001 Regorafenib | 18 Years - | CStone Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
